Inflammatory Bowel Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), | Key Companies – Gilead Sciences, Takeda, Pfizer, GlaxoSmithKline

Inflammatory Bowel Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), | Key Companies - Gilead Sciences, Takeda, Pfizer, GlaxoSmithKline
DelveInsight Business Research LLP
DelveInsight’s “Inflammatory bowel disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Inflammatory bowel disease, historical and forecasted epidemiology as well as the Inflammatory bowel disease market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Inflammatory bowel disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Inflammatory bowel disease, historical and forecasted epidemiology as well as the Inflammatory bowel disease market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Inflammatory Bowel Disease Overview

Inflammatory Bowel Disease (IBD) is a complex chronic disease resulting from the dysregulation of the immune system triggered by genetic, epigenetic, microbial, and environmental factors. Ulcerative colitis and Crohn’s disease are two forms of inflammatory bowel disease that can cause serious and debilitating symptoms and disruptions in daily life.

Crohn’s Disease is a chronic immune-mediated condition of the gastrointestinal (GI) tract. Crohn’s most commonly affects the end of the small bowel (the ileum) and the beginning of the colon, but it may affect any part of the GI tract, from the mouth to the anus. 

 

Inflammatory Bowel Disease Epidemiology Insights

The annual incidence rates of Chronic Disease  are comparable across most of the developed world. It is estimated to be 20.2 per 100,000 person-years, 12.7 per 100,000 person-years, 29.3 per 100,000 person-years and 16.5 per 100,000 person-years in North America, Europe, Australia and New Zealand, respectively. In contrast, Asia has a low incidence rate of approximately 0.54 per 100,000 person-years. Similarly, the incidence rates for UC in North America, Europe and Asia ranged from 7.6 to 19.5 per 100,000 person-years, 1.7 to 13.6 per 100,000 person-years, and 0.3 to 5.8 per 100,000 person-years, respectively. In the past, UC was considered to be slightly more prevalent; however, an increased incidence of CD in the past few decades has resulted in a trend reversal. Most recent estimates of prevalence of CD in North America are 25–300 per 100,000 person-years and that for UC are 170–250 and 43–294 per 100,000 person-years, respectively, in North America and Europe. Overall, both the incidence and prevalence of CD and UC are increasing with time. This can be attributed to a number of factors including improved sanitation, diet and medication exposures, increased IBD awareness among patients and clinicians, use of improved endoscopic and radiologic diagnostic modalities and widened health care access

Click here to learn more about the Inflammatory Bowel Disease Market Landscape

The Report Covers the Inflammatory Bowel Disease   Epidemiology Segmented by:

  • Inflammatory Bowel Disease prevalent cases 

  • Inflammatory Bowel Disease diagnosed cases 

  • Inflammatory Bowel Disease treatment cases 

  • Inflammatory Bowel Disease incident cases 

  • Inflammatory Bowel Disease cases based on age 

Inflammatory Bowel Disease Market Outlook

 The Inflammatory bowel disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Inflammatory bowel disease market trends by analyzing the impact of current Inflammatory bowel disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of the Inflammatory bowel disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Inflammatory bowel disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 According to DelveInsight, the Inflammatory bowel disease market in 7MM is expected to witness a major change in the study period 2019-2032.

 Key Companies Working in the Inflammatory Bowel Disease Market

  • Gilead Sciences 

  • Takeda 

  • Pfizer 

  • GlaxoSmithKline 

  • And many others 

 

Inflammatory Bowel Disease Therapies Covered and Analyzed in the Report:

  • Filgotinib

  • CT-P13

  • Remicade

  • Infliximab

  •  MT-1303

Learn more about the Key Companies and Emerging Therapies in the Inflammatory Bowel Disease Market.

Table of Contents 

  1. Key Insights 

  2. Inflammatory Bowel Disease Introduction 

  3. Executive Summary of Inflammatory Bowel Disease     

  4. Disease Background and Overview

  5. Epidemiology and patient population

  6. Inflammatory Bowel Disease Emerging Therapies

  7. Inflammatory Bowel Disease Market Outlook

  8. Market Access and Reimbursement of Therapies

  9. Market Drivers 

  10. Market Barriers 

  11. Appendix

  12. Report Methodology

  13. DelveInsight Capabilities

  14. Disclaimer

Learn about the detailed offerings of the report @ Inflammatory Bowel Disease Market Outlook.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services


Posted

in

by

Tags: